WASHINGTON (AP) — So-called mRNA vaccines saved millions of lives during the COVID-19 pandemic — and now scientists are using that Nobel Prize-winning technology to try to develop vaccines and ...

He claimed mRNA vaccines weren't effective against certain infections. The Department of Health and Human Services (HHS) announced this week it is beginning a "coordinated wind-down" of federally ...

Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing ...

A major bottleneck in curing HIV (human immunodeficiency virus) is that the virus can hide in an inactive form within resting white blood cells, which play a crucial role in coordinating the immune ...

Jonathan Kagan has his sights set on next year, when the Harvard scientist plans to start clinical trials on an experimental cancer treatment based on the same technology — messenger RNA — that ...

Topline results were announced from a phase 3 study evaluating Moderna’s cytomegalovirus vaccine candidate, mRNA-1647.

The vaccine, known as mRNA-1647, showed disappointing efficacy against primary CMV infection in healthy women, ranging from just 6% to 23% depending on the case definition used. As a result, Moderna ...

Moderna said its cytomegalovirus (CMV) vaccine, mRNA-1647, failed to prevent infection in women of childbearing age in a ...

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...

Transfer ribonucleic acid (tRNA) is a type of RNA molecule that helps decode a messenger RNA (mRNA) sequence into a protein. tRNAs function at specific sites in the ribosome during translation, which ...